Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report
NEW DELHI: The Indian Pharmaceutical Market continued its upward momentum in April 2025, registering a strong 7.8 per cent year-on-year growth with total sales reaching Rs 19,711 crore, according to…
Diabetes drug shows promise for treating prostate cancer
An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which…
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
Biocon, India’s leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics…
India puts in place a health emergency plan for Jammu and Kashmir, transports portable hospitals to Poonch, Uri
New Delhi: The government has put in place a health emergency plan for Jammu and Kashmir amid continuing cross-border shelling from Pakistan, dispatching two portable hospitals in the affected areas…
CEO speaks: India’s AI-Powered Pharma Revolution: The Next Big Wave in Healthcare
A digital revolution is sweeping through the pharmaceutical industry, and it’s powered by artificial intelligence (AI). From automating drug discovery to making clinical trials more efficient and driving breakthroughs in…
Suven Pharmaceuticals renamed as Cohance Lifesciences
Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from Suven Pharmaceuticals to Cohance Lifesciences, with effect from…
Dabur misses estimates, profit drops 8% to Rs 320 crore
Dabur India on Wednesday reported an 8.4% year-on-year decline in net profit for the January–March quarter, at Rs 320.13 crore. The figure fell short of Bloomberg’s consensus estimate of Rs…
Russian govt to take additional measures to avoid drug shortages
The Russian government will consider registering next-in-class drugs based on data from the second phase of clinical trials (CT) as well as will implement other measures in order to avoid…
Neutral Alembic Pharma; target of Rs 930: Motilal Oswal
Motilal Oswal’s research report on Alembic Pharma Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in…
Trump’s new executive orders may hit Indian Pharma exports, reshape global drug supply chains: Report
The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market,…
